ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0863

Effect of Glucocorticoids on Patient Reported Outcomes in Patients Started on a Biologic Consensus Treatment Plan for the ‘First Line Options for Systemic JIA Treatment’ (FROST) Study

Karen James1, George Tomlinson2, Tim Beukelman3, Laura Schanberg4, Anne Dennos5, VIncent Del Gaizo6, Marian Jelinek7, Erin Pfeifer8, Shalini Mohan9 and Yukiko Kimura10, 1University of Utah, Salt Lake City, UT, 2University of Toronto, Toronto, ON, Canada, 3Childhood Arthritis and Rheumatology Research Alliance (CARRA), Birmingham, AL, 4Duke University Medical Center, Durham, NC, 5Duke University, Durham, NC, 6Childhood Arthritis and Rheumatology Research Alliance (CARRA), Durham, NC, 7Childhood Arthritis and Rheumatology Research Alliance (CARRA), Duke, 8Genentech, Englewood, NJ, 9Genentech, San Diego, 10Hackensack Meridian Health, New York, NY

Meeting: ACR Convergence 2022

Keywords: glucocorticoids, Juvenile idiopathic arthritis, Patient reported outcomes, Still's disease

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 13, 2022

Title: Pediatric Rheumatology – Clinical Poster I: JIA

Session Type: Poster Session B

Session Time: 9:00AM-10:30AM

Background/Purpose: Systemic Juvenile Idiopathic Arthritis (sJIA) is a systemic autoinflammatory disease characterized by high fevers, rash and arthritis. Current treatment regimens often involve biologic (anti-IL-1 or anti-IL6) medications, glucocorticoids (GC), or both. Both treatments and disease can have a significant impact on health-related quality of life (HRQoL). GC may be used in addition to biologic treatment for many reasons, including concern that the biologic medication alone may not be enough to control severe systemic disease or pain. This study aimed to evaluate the impact of early use of GC on HRQoL in newly diagnosed sJIA patients started on a biologic treatment.

Methods: Data on patient reported outcomes (PROs) was collected as part of the FiRst-line Options for Systemic juvenile idiopathic arthritis Treatment (FROST) study, a non-randomized prospective observational study of outcomes in children with newly diagnosed sJIA treated by one of 4 Childhood Arthritis and Rheumatology Research Alliance (CARRA) consensus treatment plans (CTPs) for sJIA enrolled in the CARRA Registry. Treatment, including GC use, was at the discretion of the treating provider. This analysis included only subjects treated with a biologic (anti-IL1 or anti-IL6) CTP. Early GC usage was defined as any use reported at the baseline, 2 week, or 1 month visit. Patients were evaluated by their treating physician at baseline, week 2, and months 1, 3, 6, 9, and 12; PROs collected at these visits included patient global disease assessment and Patient Reported Outcomes Measurement Information Systems (PROMIS) short forms. Home PROs on pain, fever, and rash were collected every 2 days for 4 weeks, then weekly for 3 months. Generalized estimating equations and linear mixed effects models were used to compare PROs between GC treatment groups.

Results: 63 of the 73 subjects enrolled in FROST began one of the biologic CTPs. The median age was 7 years (IQR 4.0, 11.3), and 64% were male. 31 (49%) received GC within the first month. Baseline disease characteristics of subjects by GC treatment group are shown in table 1. Subjects treated with GC had a higher median baseline joint count and physician global assessment of disease activity, but a lower CRP and patient global assessment of disease activity. (Table 1). No significant differences were noted in patient reported pain from home over the first 12 weeks in those receiving GC in the first month vs those not (p=0.71, Figure 1), or over the first year of follow-up in terms of PROMIS scores on pain interference (p=0.73), fatigue (p=0.87), mobility(p=0.28), or upper extremity function (p=0.18), after adjusting for time and baseline joint count. (figure 2)

Conclusion: Although GC’s were given at the providers’ discretion, patients had very similar baseline characteristics regardless of GC treatment group. There were no significant differences in the trend of improvement in most PROs over the first year of treatment, with point estimates for mobility, pain interference, and upper extremity function appearing better in the group not treated with GC, even after adjusting for joint count. This suggests that early GC use, when used with biologics, may not have significant effects in the patient’s experience of their disease.

Supporting image 1

Table 1: Baseline Characteristics of subjects Stratified by any steroid use in the first month vs No steroid use in the first month. cJADAS_10*: Clinical Juvenile Arthritis Disease Activity Score 10; JADAS_10: Juvenile Arthritis Disease Activity Score 10. SMD: standardized mean difference

Supporting image 2

Figure 1. Trends in home reported pain scores of individual patients over the first 12 weeks of enrollment, comparing those who received early glucocorticoids in the first month vs those who did not. The gold represents the first month of data during the exposure period.

Supporting image 3

Figure 2: Patient-Reported Outcome Measures Information System Short form scores over the first 12 months. The fitted curves are estimates from a linear mixed model comparing outcomes in months 1_12 according to receipt of GC in the first month. The model has been adjusted for the baseline joint count. A higher T-score in a domain represents more of the domain being measured: for A and B (pain interference and fatigue), lower is better, and for C and D (mobility and upper extremity), higher is better.


Disclosures:

K. James, None; G. Tomlinson, None; T. Beukelman, Novartis, UCB; L. Schanberg, UCB, Sanofi; A. Dennos, None; V. Del Gaizo, None; M. Jelinek, None; E. Pfeifer, genentech; S. Mohan, genentech; Y. Kimura, Genentech.

To cite this abstract in AMA style:

James K, Tomlinson G, Beukelman T, Schanberg L, Dennos A, Del Gaizo V, Jelinek M, Pfeifer E, Mohan S, Kimura Y. Effect of Glucocorticoids on Patient Reported Outcomes in Patients Started on a Biologic Consensus Treatment Plan for the ‘First Line Options for Systemic JIA Treatment’ (FROST) Study [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/effect-of-glucocorticoids-on-patient-reported-outcomes-in-patients-started-on-a-biologic-consensus-treatment-plan-for-the/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/effect-of-glucocorticoids-on-patient-reported-outcomes-in-patients-started-on-a-biologic-consensus-treatment-plan-for-the/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology